Founding Director, Center for Cancer Economics, Professor of Oncology @Rabinmedical_. @TelAvivUni.
Israel
Joined July 2011
- Tweets1.7K
- Following61
- Followers1.5K
- Likes1.1K
Daniel Goldstein MD retweeted
Happy To Share Our Paper published In Lancet Oncology.
It is joint venture between myself and @ManjuSengar7 and Dr Roni Levin And @drdgoldstein from Israel 🇮🇱.
We closely looked at Subcut IO drugs approvals and discuss that even though sub cut formulations are more convenient they may actually prolong patents and may delay entry of Biosimilar IO drugs .
Wolf 🐺 in Sheep 🐑 clothing.
Classic essay in Pharmaco Economics 🙂
@TheLancetOncol @Larvol @brunolarvol @OncBrothers @MedwatchKate
thelancet.com/journals/lanon…
Great work by Robert Langreth from Bloomberg News in reporting our work related to the opportunities of low-dosed immunotherapy.
The concept is increasingly becoming mainstream.
bloomberg.com/features/2025-… via @business
Some personal news…. I’m delighted to announce that I’m returning full time to the Davidoff center of Rabin Medical Center. I will be opening the Center for Health Economics and Medical Decision Making, which will focus on Education, Research and Consultancy. 1/n
I will continue my clinical work as a GU oncologist. I have great thanks to the Director of the Davidoff Center, @GalMarkel, and my long-time colleague and friend Dr Eli Rosenbaum who have provided great support in making this happen, and who share and appreciate the vision. 2/n
Our new paper - the tyranny of non-inferiority.
The tyranny of Non -inferiority Trials. Excellent view 👌 by @ian_tannock @drdgoldstein @TheLancetOncol
Vote for Chris - he definitely gets my full support!
Honoured to be standing for @uicc Board of Directors.
Fewer cancers, better survival, fairer access to care through collaboration and partnership, is why I am standing.
See my FB post for more info: facebook.com/share/p/eEXU3Nt…
#UICC #CancerEquity #BetterFairerCancerCare
Our new paper about overuse of PETCT using real world data from Clalit in Israel.
📣 Choosing Wisely in oncology: are guidelines effective at preventing unnecessary diagnostics? The example of surveillance positron emission tomography for patients with localised colorectal cancer
Check out this #originalresearch from @drdgoldstein and colleagues: bmjoncology.bmj.com/content/…
#oncoalert @oncoalert
Really great pleasure to help to run this workshop in Hong Kong. Thanks to Vivian Lee for amazing organization, and to @herbloong for being a great host to satisfy my foodie instincts!
Thanks @drdgoldstein for coming all the way from 🇮🇱 to 🇭🇰 to share insights and experiences in #pharmacoeconomics. Organised by #ProfVivianLee and colleagues of @cuhkpharmacy Very engaged workshop together with stakeholders from #academia, #industry, #patientsrepresentatives and the #HospitalAuthority @CUHKMedicine @hkumed
Daniel Goldstein MD retweeted
Thank you @TheLancetOncol for the shout out to Common Sense Oncology movement in the latest editorial. The editorial is excellent and open access. We highly encourage you to read it in its entirety.
thelancet.com/journals/lanon…
US Senator now getting involved in cancer drug dosing issues
Totally love this. I’m proud to be an “old-fashioned” doctor!
Totally flattered by all who tagged me when they shared this piece. As @VPrasadMDMPH said, I wish I had written it.
Daniel Goldstein MD retweeted
Join us by Zoom for the first open plenary session of @csoncol . Register here- zoom.us/webinar/register/WN_…
Common Sense Oncology leadership team is having its first annual meeting next week in Montreal. Our opening plenary session will be open to all CSO members. Join us by zoom for the LIVE plenary session with these leaders in our field.
Register for zoom link here- zoom.us/webinar/register/WN_…
Daniel Goldstein MD retweeted
🎧 Catch the latest episode of the @Uromigos (@brian_rini, @tompowles1) with @drdgoldstein on dosing issues and dosing changes in drugs such as #nivolumab and #pembrolizumab, as well as other immune checkpoint inhibitors.
👂 Listen Here: buff.ly/3W7fDcG
Daniel Goldstein MD retweeted
If you are an oncologist/trainee interested in the Common Sense Oncology movement you can contribute here @csoncol #commonsenseoncology:
Our new paper on class effects in oncology. A great opportunity for savings for health care payers, without impacting outcomes.
A new review suggests that many cancer drugs are interchangeable, which could potentially lead to significant cost savings for patients and health systems.
@drdgoldstein
bmjoncology.bmj.com/content/…
Big problem of IO access in control arm as trial was performed in countries lacking access. 40% of patients in control arm who got systemic therapy at relapse didn’t get IO. Censoring also an issue. The “positive” OS isn’t real. More info here…..ascopubs.org/doi/full/10.120…
Why pembrolizumab worked and nivo did not in adjuvant RCC ? Any theory? @asco @OncoAlert #GU24 @DrChoueiri @tompowles1 @montypal @dr_yakupergun @DrYukselUrun
